Press releases
GSK and Help for Heroes partner to support the rehabilitation of wounded servicemen and women in the UK
GSK and Help for Heroes today announced a new partnership to help support injured British armed forces personnel successfully transition back into civilian life. The partnership will focus on the creation of a specialist 'Wellness Centre' at Tedworth House, a Personnel Recovery and Assessment Centre located in Wiltshire.
GSK statement in response to the Prime Minister’s speech on life sciences
"The Government’s strategy for Life Sciences is a very important next step on the journey to make the UK the best place in the world to locate pharmaceutical investment. The actions on research and manufacturing will further strengthen the attractiveness of the UK and most importantly the results of the Innovation Review should ensure that the NHS is a stronger adopter of innovative medicines and technology, ensuring that all patients can benefit from cost-effective treatments and interventions approved by NICE.
Regulatory Update: GlaxoSmithKline submits additional information for candidate meningococcal and Hib combination vaccine
GlaxoSmithKline [NYSE:GSK] today submitted additional information to the U.S. Food and Drug Administration (FDA) in support of the Biologics License Application (BLA) for the candidate meningococcal and Hib combination vaccine MenHibrix® (Hib-MenCY-TT). This information was submitted in response to the September 2011 Complete Response letter received from the FDA.
Reporting on a core earnings basis will begin with effect from Q1 2012
Go to the Presentations and webcasts page for the full announcement.
GSK welcomes GAVI Alliance decision to introduce vaccines against cervical cancer and rubella in the world’s poorest countries
GlaxoSmithKline today welcomed the decision of the GAVI Board to provide funding to facilitate the provision of cervical cancer immunisation programmes and rubella vaccination, across the world’s poorest countries.
GlaxoSmithKline welcomes innovative knowledge-sharing collaboration to break deadlock in antibiotic discovery and development
GlaxoSmithKline (GSK) today welcomes the European Commission’s commitment to promote collaborative research efforts to develop new antibiotics against the growing threat from resistant bacteria.
GSK receives initial data from the first completed phase lll study of albiglutide in type 2 diabetes
Head-to-head study primary end point did not meet non-inferiority, but results support progression towards registration
Data published in The Lancet Oncology support high efficacy previously demonstrated by Cervarix® (HPV 16 and 18 vaccine) against precancerous cervical lesions caused by HPV 16 and 18 and also efficacy against certain other cancer-causing HPV types
An analysis published today in TheLancet Oncology reinforces previous findings showing that GlaxoSmithKline’s Cervarix®, provided protection against advanced precancerous lesions (CIN3+), above that expected from a vaccine that protects against human papillomavirus (HPV) types 16 and 18. CIN3+ is the immediate step before invasive cervical cancer and data showing protection against this type of lesion are considered the most stringent evidence of potential cervical cancer prevention.1
GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia
Full results from ENABLE 1 and initial data from ENABLE 2 presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases
GlaxoSmithKline reaches agreement in principle to resolve multiple investigations with US Government
- $3 billion settlement covered by existing legal provisions - Fundamental changes to US compliance, marketing and selling procedures implemented in recent years
